Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study
is accompanied by
Abstract
Purpose:
Phosphodiesterase type 5 inhibitors are widely used to treat erectile dysfunction. Preliminary data have suggested phosphodiesterase type 5 inhibitor efficacy in men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
Materials and Methods:
After a 4-week placebo run-in period 1,058 men with benign prostatic hyperplasia lower urinary tract symptoms were randomly allocated to receive 12-week, once daily treatment with placebo or tadalafil (2.5, 5, 10 or 20 mg).
Results:
The International Prostate Symptom Score least squares mean change from baseline to end point was significantly improved for 2.5 (−3.9, p = 0.015), 5 (−4.9, p <0.001), 10 (−5.2, p <0.001) and 20 mg (−5.2, p <0.001) tadalafil compared to placebo (−2.3). International Prostate Symptom Score improvements at 4, 8 and 12 weeks were significant for all tadalafil doses and they demonstrated a dose-response relationship. Tadalafil (2.5 mg) significantly improved the International Prostate Symptom Score obstructive subscore and the International Index of Erectile Function-Erectile Function domain, the latter in sexually active men with a history of erectile dysfunction. Statistically significant improvements were noted for 5, 10 and 20 mg tadalafil compared to placebo, as assessed by the International Prostate Symptom Score irritative and obstructive subscores, International Prostate Symptom Score Quality of Life, Benign Prostatic Hyperplasia Impact Index (nonsignificant for 10 mg), Global Assessment Question and International Index of Erectile Function-Erectile Function domain. No statistically significant effect of treatment compared to placebo was noted for peak flow at any tadalafil dose. Treatment emergent adverse events were infrequent in all tadalafil groups.
Conclusions:
Once daily tadalafil demonstrated clinically meaningful and statistically significant efficacy and it was well tolerated in men with benign prostatic hyperplasia lower urinary tract symptoms. Of the doses studied 5 mg tadalafil appeared to provide a positive risk-benefit profile.
References
- 1 : Urologic Diseases in America Project: benign prostatic hyperplasia. J Urol2005; 173: 1256. Link, Google Scholar
- 2 : Natural history of prostatism: risk factors for acute urinary retention. J Urol1997; 158: 481. Link, Google Scholar
- 3 : Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol1995; 153: 669. Link, Google Scholar
- 4 : ‘Prostate-related symptoms’ in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol1994; 74: 542. Google Scholar
- 5 : American Urological Association 2006. 2008. URL:http://www.auanet.org/guidelines/bph.cfm. Accessed March 2008. Google Scholar
- 6 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349: 2387. Google Scholar
- 7 : The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. Curr Urol Rep2004; 5: 251. Google Scholar
- 8 : Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol2006; 61: 280. Google Scholar
- 9 : Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol2001; 166: 2484. Link, Google Scholar
- 10 : Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology2007; 148: 1019. Google Scholar
- 11 : Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol2007; 178: 2040. Link, Google Scholar
- 12 : Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol2003; 170: 659. Link, Google Scholar
- 13 : Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int2005; 96: 1073. Google Scholar
- 14 : Alpha-blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int2008; 101: 319. Google Scholar
- 15 : Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn2007; 26: 928. Google Scholar
- 16 : Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. Urology1994; 44: 683. Google Scholar
- 17 : Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol2001; 86: 304. Google Scholar
- 18 : Nitric oxide and relaxation of pig lower urinary tract. Br J Pharmacol1992; 106: 416. Google Scholar
- 19 : Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol2007; 177: 1401. Link, Google Scholar
- 20 StatXact Procs for SAS Users: Statistical Software for Exact Nonparametric Inference (User Manual), version 6. Cambridge, Massachusetts: Cytel Software Corp2004. Google Scholar
- 21 : Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. J Urol1995; 154: 1770. Link, Google Scholar
- 22 : Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging2002; 19: 135. Google Scholar
- 23 : Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol2007; 177: 1071. Link, Google Scholar
- 24 : A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol2008; 53: 1236. Google Scholar
- 25 : Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol2006; 50: 351. Google Scholar
- 26 : Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res2007; 19: 95. Google Scholar
